PMID- 26515910
OWN - NLM
STAT- MEDLINE
DCOM- 20160609
LR  - 20220408
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 110
IP  - 3
DP  - 2015 Dec
TI  - Risk of type 2 diabetes mellitus in female breast cancer patients treated with 
      morphine: A retrospective population-based time-dependent cohort study.
PG  - 285-90
LID - S0168-8227(15)00405-2 [pii]
LID - 10.1016/j.diabres.2015.10.005 [doi]
AB  - AIMS: We aimed to examine whether morphine treatment is associated with type 2 
      diabetes mellitus (T2DM) in female breast cancer patients. METHODS: We conducted 
      a retrospective cohort analysis of the Longitudinal Health Insurance Database for 
      Catastrophic Illness Patients in Taiwan. A total of 31,112 women with breast 
      cancer without T2DM history during the period 2000-2005 were identified, divided 
      into morphine and non-morphine users (8071 and 23,041 patients, respectively), 
      and the hazard ratios of newly diagnosed T2DM during the period 2005-2010 were 
      calculated. We used a Cox proportional hazard model with time-dependent exposure 
      covariates to estimate the risk of T2DM. The dosage of morphine was counted as 
      defined daily dose and its effect was assessed by multivariable Cox proportional 
      hazard regression controlling age, Charlson comorbidity index, outpatient 
      department visits, antipsychotics, and breast cancer drugs. RESULTS: Morphine 
      users were 1.24 times more likely to suffer from T2DM than non-morphine users 
      (95% CI=1.04-1.49). Risk increased slightly with the morphine dosage, in patients 
      aged 35-49 years, and with tamoxifen, aromatase inhibitors, and antipsychotics 
      treatment. CONCLUSIONS: The incidence of T2DM is associated with morphine 
      treatment in female breast cancer patients. A higher risk was observed in 
      patients aged 35-49 years using higher dose of morphine, and may be increased by 
      tamoxifen and aromatase inhibitors.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Yang, Szu-Pang
AU  - Yang SP
AD  - Yang's ENT Clinic, Taichung, Taiwan.
FAU - Muo, Chih-Hsin
AU  - Muo CH
AD  - Department of Public Health, China Medical University, Taichung, Taiwan; 
      Management Office for Health Data, China Medical University Hospital, Taichung, 
      Taiwan.
FAU - Wang, I-Kuan
AU  - Wang IK
AD  - Department of Internal Medicine, China Medical University Hospital, Taichung, 
      Taiwan; Division of Kidney Disease, College of Medicine, China Medical 
      University, Taichung, Taiwan.
FAU - Chang, Yen-Jung
AU  - Chang YJ
AD  - Department of Health Promotion and Health Education, National Taiwan Normal 
      University, Taipei, Taiwan.
FAU - Lai, Shih-Wei
AU  - Lai SW
AD  - Department of Family Medicine, China Medical University Hospital, Taichung, 
      Taiwan; China Medical University, Taichung, Taiwan.
FAU - Lee, Cynthia Wei-Sheng
AU  - Lee CW
AD  - China Medical University, Taichung, Taiwan; Center for Drug Abuse and Addiction, 
      China Medical University Hospital, Taichung, Taiwan. Electronic address: 
      T22529@mail.cmuh.org.tw.
FAU - Morisky, Donald E
AU  - Morisky DE
AD  - Department of Community Health Sciences, UCLA Fielding School of Public Health, 
      Los Angeles, CA, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151022
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Aromatase Inhibitors)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 76I7G6D29C (Morphine)
RN  - TJ2M0FR8ES (Megestrol Acetate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aromatase Inhibitors/therapeutic use
MH  - Breast Neoplasms/*drug therapy
MH  - Diabetes Mellitus, Type 2/*epidemiology
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Megestrol Acetate/therapeutic use
MH  - Middle Aged
MH  - Morphine/*adverse effects/therapeutic use
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Taiwan/epidemiology
MH  - Tamoxifen/therapeutic use
MH  - Young Adult
OTO - NOTNLM
OT  - Breast cancer
OT  - Cohort analysis
OT  - Morphine
OT  - Type 2 diabetes mellitus
EDAT- 2015/10/31 06:00
MHDA- 2016/06/10 06:00
CRDT- 2015/10/31 06:00
PHST- 2015/02/18 00:00 [received]
PHST- 2015/08/24 00:00 [revised]
PHST- 2015/10/02 00:00 [accepted]
PHST- 2015/10/31 06:00 [entrez]
PHST- 2015/10/31 06:00 [pubmed]
PHST- 2016/06/10 06:00 [medline]
AID - S0168-8227(15)00405-2 [pii]
AID - 10.1016/j.diabres.2015.10.005 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2015 Dec;110(3):285-90. doi: 
      10.1016/j.diabres.2015.10.005. Epub 2015 Oct 22.